News Search Results
Oct 15, 2025, 07:05 ET REGENXBIO to Participate in Upcoming Investor Conferences
II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving
More news about: REGENXBIO Inc.
Oct 09, 2025, 07:05 ET REGENXBIO Announces Presentation at the American Academy of Ophthalmology 2025 Annual Meeting
collaboration with AbbVie, is an investigational one-time gene therapy and potential first-in-class treatment for wet age-related macular degeneration (wet AMD) and DR. Presentation: Suprachoroidal surabgene lomparvovec (sura-vec, ABBV-RGX-314): First time 2-year
More news about: REGENXBIO Inc.
Oct 08, 2025, 19:30 ET Astellas to Present New Data on IZERVAY™ (avacincaptad pegol intravitreal solution) in Geographic Atrophy at AAO 2025 Annual Meeting
small specks floating in your vision, flashes of light, or increased sensitivity to light. There is a risk of developing wet AMD with IZERVAY. You should report any symptoms (visual distortions such as straight lines seeming bent, deterioration in vision, dark spots, loss of
More news about: Astellas Pharma Inc.
Oct 06, 2025, 07:05 ET REGENXBIO Announces Completion of Enrollment in Pivotal Trials of Subretinal Surabgene Lomparvovec for Wet AMD
About Wet AMDWet AMD is characterized by loss of vision due to new, leaky blood vessel formation in the retina. Wet AMD is a significant cause of vision loss in the United States, Europe and Japan, with up to 2 million people living with wet AMD in these geographies alone.
More news about: REGENXBIO Inc.
Sep 29, 2025, 07:05 ET REGENXBIO Announces Presentation at the World Muscle Society
MPS I, both in partnership with Nippon Shinyaku; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO's AAV
More news about: REGENXBIO Inc.
Sep 05, 2025, 07:05 ET REGENXBIO Presents Positive Twelve-Month Pivotal Data from Phase I/II/III CAMPSIITE® Trial of RGX-121 for Treatment of MPS II
II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving
More news about: REGENXBIO Inc.
Aug 28, 2025, 07:05 ET REGENXBIO to Participate in Upcoming Investor Conferences
II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving
More news about: REGENXBIO Inc.
Aug 18, 2025, 17:00 ET REGENXBIO Announces FDA Review Extension of BLA for RGX-121 to Treat Patients with MPS II
II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving
More news about: REGENXBIO Inc.
Aug 13, 2025, 16:00 ET Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2025 Financial Results
DAYBREAK wet AMD study – topline data expected 3Q 2026Completed the manufacturing and release of BLA-facing commercial-scale batches in Kodiak's URSUS facilityKSI-501 – Phase 3 topline data expected in 3Q 2026 (12 months)Phase 3 DAYBREAK wet AMD study
More news about: Kodiak Sciences Inc.
Aug 07, 2025, 07:05 ET REGENXBIO Reports Second Quarter 2025 Financial Results and Operational Highlights
enrolled.Sura-vec for the Treatment of Wet AMD (Subretinal Delivery) Enrollment is ongoing in the ATMOSPHERE® and ASCENT™ pivotal trials. Topline results are expected in 2026. Sura-vec is on track to be the first approved gene therapy for wet AMD.Sura-vec for
More news about: REGENXBIO Inc.
Aug 07, 2025, 07:00 ET REGENXBIO Announces Pivotal Program for Surabgene Lomparvovec in Diabetic Retinopathy
continued investment across the broader sura-vec program. AbbVie will independently advance and pay all costs for a new Phase III ACHIEVE trial in wet AMD. This randomized controlled trial will assess the potential reduction in injection burden and preservation of long-term vision of sura-vec compared
More news about: REGENXBIO Inc.
Jul 31, 2025, 07:05 ET REGENXBIO to Host Conference Call on August 7 to Discuss Second Quarter 2025 Financial Results and Operational Highlights
II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving
More news about: REGENXBIO Inc.
Jul 28, 2025, 02:00 ET Alteogen Receives Positive CHMP Opinion for Aflibercept Biosimilar, 'EYLUXVI® (ALT-L9)'
efficacy and comparable safety, immunogenicity, and pharmacokinetics (PK) profiles between EYLUXVI® and reference aflibercept in patients with wet AMD. Meanwhile, Alteogen licensed the development and commercialization rights for its anti-cancer drug Herceptin® biosimilar, ALT-L2,
More news about: Alteogen Inc.
Jul 10, 2025, 11:54 ET REGENXBIO Announces Publication of Preclinical Results Demonstrating Functional Benefits of Novel Microdystrophin Construct in RGX-202 Investigational Gene Therapy for Duchenne Muscular Dystrophy
II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving
More news about: REGENXBIO Inc.
Jun 05, 2025, 07:05 ET REGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202
II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving
More news about: REGENXBIO Inc.
Jun 02, 2025, 07:05 ET REGENXBIO to Host Webcast Discussing Interim Functional Data from the Phase I/II AFFINITY DUCHENNE® Trial of RGX-202
II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving
More news about: REGENXBIO Inc.
May 23, 2025, 06:12 ET Weekly Recap: 14 Health Press Releases You Need to See
top-line data readout and BLA submission for RGX-202 for Duchenne, and top-line data readouts for two pivotal studies of subretinal ABBV-RGX-314 for wet AMD," said Mitchell Chan Chief Financial Officer of REGENXBIO.
More news about: PR Newswire
May 19, 2025, 16:05 ET REGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 Million
top-line data readout and BLA submission for RGX-202 for Duchenne, and top-line data readouts for two pivotal studies of subretinal ABBV-RGX-314 for wet AMD," said Mitchell Chan Chief Financial Officer of REGENXBIO. "Along with fueling our late-stage activities, this transaction
More news about: REGENXBIO Inc.
May 14, 2025, 16:15 ET Kodiak Sciences Announces Recent Business Highlights and First Quarter 2025 Financial Results
to topline dataPhase 3 DAYBREAK wet AMD study – update on enrollment completion and expected timeline to topline dataUpdate on Biologics License Application (BLA) facing activitiesKSI-501:Phase 3 DAYBREAK wet AMD study – update on enrollment completion
More news about: Kodiak Sciences Inc.
May 13, 2025, 07:05 ET REGENXBIO Announces FDA Acceptance and Priority Review of the BLA for RGX-121 for MPS II
II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving
More news about: REGENXBIO Inc.
May 12, 2025, 16:05 ET REGENXBIO Reports First Quarter 2025 Financial Results and Recent Operational Highlights
the Treatment of Wet AMD (Subretinal Delivery) Enrollment is ongoing in the ATMOSPHERE® and ASCENT™ pivotal trials. REGENXBIO and AbbVie expect to share topline results in 2026. Sura-vec is on track to be the first approved gene therapy for wet AMD.Sura-vec
More news about: REGENXBIO Inc.
May 08, 2025, 07:05 ET REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 28th Annual Meeting
II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving
More news about: REGENXBIO Inc.
May 06, 2025, 07:05 ET REGENXBIO to Participate in Upcoming Investor Conferences
MPS I, both in partnership with Nippon Shinyaku; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO's AAV
More news about: REGENXBIO Inc.
May 01, 2025, 23:43 ET Kodiak Sciences Data at ARVO 2025 Highlight Power and Versatility of ABC Platform in Addressing Complex Multifactorial Ocular Diseases
Here we present new data on a promising therapeutic strategy to treat GA by combining complement regulators with an anti-VEGF antibody to prevent wet AMD conversion and anti-IL-6 antibody to further reduce GA progression, to achieve potent concurrent inhibition of complement pathway activation and VEGF
More news about: Kodiak Sciences Inc.
May 01, 2025, 09:00 ET Astellas to Present New Data in Geographic Atrophy at Upcoming Ophthalmology Annual Congresses
increased number of small specks floating in your vision, flashes of light, or increased sensitivity to light.There is a risk of developing wet AMD with IZERVAY. You should report any symptoms (visual distortions such as straight lines seeming bent, deterioration in vision, dark spots, loss of
More news about: Astellas Pharma Inc.